Massachusetts Institute of Technology

Bristol-myers Squibb Compnay

Tufts University

Alyssa H Antropow

Deqiang Niu

T G Murali Dhar

John V Duncia

Joseph Anthony Tino

Robert J Cherney

Daniel S Gardner

Ramesh Kumar Sistla

Boris M Seletsky

Manoranjan Panda

Venkatram Reddy Paidi

Srinivasan Thangathirupathy

Julio Hernan Cuervo

Xiao Zhu

Mohammad Movassaghi

Kumaravel Selvakumar

Vijaya Kumar Cm

Mallikarjun Reddy Sura

Tirupathi Rao Alajangi

Krishna Mahadevu

Piyush Agarwal

Ooha Morampudi

Audrey Graham Ross

Paul E Gormisky

Zhengdong Zhu

Guobin Miao

Rachel J Buchsbaum

Kun Xu

Jalathi S Nair

Arul Mozhi Subbiah Karuppiah

wherein and X-Xand R-R, along with other variables are as defined herein. The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.

Heterocyclic PAD4 inhibitors

The present disclosure relates to derivatized agelastatin compounds and methods for the treatment, prevention, or delay of cancer, comprising administering a therapeutically effect amount of the derivatized agelastatin compounds, a pharmaceutically acceptable salt thereof, or a composition thereof to a subject in need thereof. Methods for making the derivatized agelastatin compounds are also provided.

Potent agelastatin derivatives as modulators for cancer invasion and metastasis

Growing community of inventors

Boston, MA, United States of America

Alyssa H Antropow